Nuclear Medicine

What’s new in Nuclear Medicine – March 2021

  Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method. Jan Rekowski, Andreas Hüttmann, Christine Schmitz, Stefan P. Müller, Lars Kurch, Jörg Kotzerke, Christiane Franzius, Matthias Weckesser, Frank M. Bengel, Martin Freesmeyer, Andreas Hertel, Thomas Krohn, Jens Holzinger, Ingo Brink, Uwe Haberkorn, Fonyuy […]

Read More

What’s new in Nuclear Medicine – January 2021

Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy: A Systematic Review and Metaanalysis Arnoldo Piccardo, Pierpaolo Trimboli, Gianluca Bottoni, and Luca Giovanella J Nucl Med 2020; 61(12): 1730-5. Background: The 2015 American Thyroid Association (ATA) guidelines suggests hemithyroidectomy (lobectomy) as the first treatment for low-risk differentiated thyroid cancer […]

Read More

What’s new in Nuclear Medicine – November 2020

Clinical efficacy of 177Lu‑DOTATATE peptide receptor radionuclide therapy in thyroglobulin‑elevated negative iodine scintigraphy: A “not‑so‑promising” result compared to GEP-NETs Basu, S.; Parghane, R. V.; Naik, C. World J Nucl Med 2020; 19: 205-10. Background: Lu-177 DOTATATE is a radiolabelled somatostatin analogue which is becoming widely approved for use in the treatment of gastroenteropancreatic (GEP) neuroendocrine […]

Read More